View in EDS HTML Full Text PDF Full Text

Cost calculation model of introducing Upadacitinib and Risankizumab for adult ulcerative colitis and Crohn's disease in the Kingdom of Saudi Arabia.

Saved in:
Bibliographic Details
Title: Cost calculation model of introducing Upadacitinib and Risankizumab for adult ulcerative colitis and Crohn's disease in the Kingdom of Saudi Arabia.
Authors: Mosli, Mahmoud H.1 (AUTHOR), Almutairdi, Abdulelah A.2,3 (AUTHOR), Alshahrani, Abdullah M.4 (AUTHOR), Alkhurmi, Abdulrahman M.5 (AUTHOR), Fasseeh, Ahmad N.6,7 (AUTHOR), Anwar, Ali M.8 (AUTHOR), Alharbi, Bandar M.9 (AUTHOR), Altawil, Esraa S.10 (AUTHOR), Alshareef, Haneen J.11 (AUTHOR), Alqasim, Hussain A.12 (AUTHOR), Alharbi, Ibtisam H.13 (AUTHOR), El-Fass, Kareem A.7 (AUTHOR) Kareem.elfass@syreon.eu, Alanizy, Layla N.14 (AUTHOR), Almehizia, Rayd A.15,16 (AUTHOR), Hren, Rok17,18 (AUTHOR), Iskandarani, Wael K.19 (AUTHOR), Alabdulkarim, Hana A.20,21 (AUTHOR)
Source: Saudi Journal of Gastroenterology. Jan/Feb2026, Vol. 32 Issue 1, p66-78. 13p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:13193767
DOI:10.4103/sjg.sjg_245_25